Pharma, Olysio sales boost J&J 1Q earnings
This article was originally published in Scrip
Pharmaceuticals maintained their growing importance to Johnson & Johnson's bottom line in the first quarter of 2014 as prescription drug sales grew in the double digits while medical device and diagnostic (MD&D) sales stabilized and revenue from over-the-counter medicines and other consumer health products declined.
You may also be interested in...
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.